EUDAMED Is Mandatory: Why Device Data Governance Now Belongs in Your Quality System

EUDAMED has moved from future-state planning to operational reality.

As of May 28, 2026, the first four EUDAMED modules are mandatory to use: Actor Registration, UDI and Device Registration, Notified Bodies and Certificates, and Market Surveillance. For medical device and IVD manufacturers, this is not just an EU regulatory affairs milestone. It is a quality system maturity test.

The reason is simple. EUDAMED depends on device data that should already be controlled, current, and traceable inside the manufacturer's own system. If that data is fragmented internally, mandatory external registration makes the gaps visible.

EUDAMED turns device data into operational evidence

Many organizations have historically treated registration data as a regulatory affairs deliverable. Regulatory gathers the inputs, submits the data, and updates the file when needed. That approach becomes fragile when the data comes from many disconnected sources.

UDI attributes may come from labeling. Device descriptions may come from technical documentation. Certificate information may come from notified body correspondence. Economic operator details may involve authorized representatives, importers, and distributors. Product status may depend on manufacturing, commercial release, post-market surveillance, and change control.

EUDAMED brings these threads together. That means manufacturers need governance over the data itself, not only the final submission.

The practical question becomes: who owns each data element, what is the approved source, how is a change assessed, and how does the organization know that EUDAMED still matches the current device state?

Mandatory modules create cross-functional accountability

The first four mandatory modules affect more than one team.

Actor Registration requires correct economic operator information and Single Registration Number control. UDI and Device Registration requires accurate device identifiers, Basic UDI-DI structure, device attributes, risk class, intended purpose, and product information. Notified Bodies and Certificates requires alignment between certificates and registered devices. Market Surveillance increases the importance of clear product and operator visibility for competent authorities.

For manufacturers, this means EUDAMED readiness cannot sit in a single regulatory spreadsheet. It has to connect to product lifecycle management, technical documentation, quality records, supplier and manufacturer responsibilities, labeling, change control, and post-market surveillance.

A weak internal process can create practical problems:

• Device data in EUDAMED does not match technical documentation.
• Certificate scope is not clearly tied to registered devices.
• UDI changes are handled in labeling but not reflected in registration controls.
• Economic operator information is updated in contracts but not in regulatory data.
• A product change triggers documentation updates but no EUDAMED impact assessment.
• Legacy devices remain in circulation without clear ownership for transitional data cleanup.

These are not merely clerical issues. They can affect market access, audit readiness, notified body confidence, and the manufacturer's ability to respond quickly to regulatory questions.

EUDAMED makes change control more important

Once device data is registered, change control becomes the backbone of continued accuracy. A change to intended purpose, device variant, UDI assignment, certificate coverage, labeling, manufacturer details, or market status may have EUDAMED implications.

The quality system should make that assessment routine. Every relevant change should ask:

• Does this affect UDI or Basic UDI-DI information?
• Does this affect device registration data?
• Does this affect technical documentation consistency?
• Does this affect certificate linkage or notified body visibility?
• Does this affect economic operator responsibilities?
• Does this affect post-market, vigilance, or field action obligations?

If those questions depend on one experienced regulatory person remembering to check a spreadsheet, the process is vulnerable. The stronger model is a controlled workflow where EUDAMED impact is built into change control, with clear ownership and documented decisions.

Manufacturers should treat EUDAMED as a source-of-truth challenge

The phrase "single source of truth" is often overused, but EUDAMED makes the concept practical. Manufacturers need to know which system governs each critical data element and how that system connects to external registration obligations.

A strong EUDAMED operating model includes:

• Defined ownership for actor, device, UDI, certificate, and market status data
• Controlled sources for device attributes and technical documentation fields
• Change control triggers for registration updates
• Periodic reconciliation between EUDAMED, technical documentation, and certificates
• Training for regulatory, quality, labeling, operations, and commercial teams
• Clear escalation when data conflicts are found

This work is especially important for manufacturers with multiple products, multiple legal entities, multiple EU representatives, or portfolios that include both legacy and MDR or IVDR devices.

For IVD manufacturers, the burden can be particularly complex because IVDR transition planning, performance evidence, technical documentation updates, and notified body capacity all interact with registration readiness.

The commercial risk is real

When registration data is wrong or incomplete, the consequences are not limited to regulatory cleanup. Product launches can slow down. Distributor questions can increase. Notified body interactions can become harder. Internal teams may lose confidence in which version of the device record is authoritative.

For manufacturers expanding globally, the problem compounds. EU data requirements must coexist with FDA, Health Canada, UK, Australia, Brazil, Japan, and other market expectations. Each market may ask for different information, but the underlying product truth should be controlled once and reused intelligently.

That is why EUDAMED should not be managed as an isolated database task. It should be part of regulatory lifecycle infrastructure.

What manufacturers should do now

The first step is to perform a data governance review, not just a registration status check. Manufacturers should identify every data field required for EUDAMED and map it back to the controlled internal source.

Then they should review active and pending changes to determine whether registration impacts are being assessed consistently. If a company cannot show who approved a data element, where it came from, when it changed, and how the external registration was updated, the process needs strengthening.

Manufacturers should also schedule periodic reconciliation. This is especially useful after certificate updates, labeling changes, product launches, economic operator changes, and portfolio rationalization decisions.

Finally, leadership should understand that EUDAMED is not only a regulatory affairs workload. It is a market access and quality system control issue. It deserves resourcing, governance, and executive visibility.

How IntelaSolve helps

IntelaSolve supports Life Sciences teams across the full regulatory lifecycle, from early regulatory strategy through technical documentation, submissions, quality operations, manufacturing readiness, launch, post-market surveillance, and sustaining engineering.

For EUDAMED readiness, that connected model matters. Manufacturers need regulatory data, UDI information, technical documentation, certificates, change control, and post-market processes to work from the same controlled foundation. IntelaSolve helps reduce the burden of disconnected point solutions, manual trackers, shared drives, and email-based evidence gathering.

EUDAMED is now mandatory for the first four modules. The manufacturers that treat device data governance as part of the quality system will be better prepared for EU oversight, notified body expectations, and global portfolio growth.

Need confidence that your EUDAMED data, technical documentation, certificates, and change control process are aligned? Request an IntelaSolve demo or Compliance Readiness Analysis to identify where your device data governance needs stronger lifecycle control.